B of A Securities Downgrades Definitive Healthcare Corp. to 'Sell'
B of A Securities sets a new price target of $0.70 for Definitive Healthcare, downgrading it to 'sell', a 15.76% downside from the current price.
Key Points
- B of A Securities downgraded Definitive Healthcare Corp. to 'sell' on June 29, 2026, with a new price target of $0.70.
- B of A Securities's $0.70 price target implies 15.76% downside from Definitive Healthcare Corp.'s ($DH) current $0.83 share price.
- Shares of DH traded near $0.72 on Wednesday, with a market cap of approximately $88.7 million and a forward P/E of 4.5.
- Recent insider activity included purchases by several executives and sales by the CEO and CFO in early June 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 29, 2026, B of A Securities downgraded Definitive Healthcare Corp. (NasdaqGS: DH) to a 'sell' rating, setting a new price target of $0.70. This change reflects a cautious outlook on the company's future performance.
B of A Securities vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Definitive Healthcare Corp. Stock Up 3.6%
Shares of NasdaqGS:DH traded near $0.72 on Wednesday. The company has a market cap of about $88.7 million, with a forward P/E ratio of 4.5 and a beta of 1.328. The stock's 52-week range has been between $0.62 and $4.70, with a 50-day moving average of $0.89 and a 200-day moving average of $1.98. Definitive Healthcare's balance sheet shows a current ratio of 1.75 and a quick ratio of 1.55, with a debt-to-equity ratio of 89.06.
$DH price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Definitive Healthcare reported revenues of approximately $238.3 million, though revenue growth has been negative at -5.5%. The company's net margin is -71.5%, and it has a return on equity of -75.5%. The next earnings release is expected on August 6, 2026.
Insider Buying and Selling at Definitive Healthcare Corp.
In early June 2026, several insiders were active in trading shares of Definitive Healthcare. On June 4, Samuel Hamood, Kathleen Winters, Scott Stephenson, and Sastry Chilukuri each bought 189,190 shares. On June 1, CEO Kevin Coop sold 66,050 shares at an average price of $0.99, and CFO Casey Heller sold 164,377 shares at the same price.
Analysts Set New Price Targets
On June 29, 2026, B of A Securities downgraded Definitive Healthcare to 'sell' with a target of $0.70. Barclays maintained its 'sell' rating with a target of $1.00 on March 30, 2026, while Canaccord Genuity maintained a 'hold' with a $3.00 target on February 27, 2026. The consensus among analysts is a 'buy' recommendation, with a mean target price of $2.20 based on six analyst opinions.
About Definitive Healthcare Corp.
Definitive Healthcare Corp., headquartered in Framingham, Massachusetts, provides a software-as-a-service platform offering healthcare commercial intelligence. The platform helps clients in sectors like biopharmaceuticals and medical devices manage sales, marketing, and product development. Founded in 2011, the company is led by CEO Kevin D. Coop and employs 678 people.
Bottom Line
B of A Securities' downgrade of Definitive Healthcare reflects a more cautious view of the company's prospects. With shares trading near the lower end of their 52-week range, investors will be watching upcoming earnings closely. As a reminder, analyst ratings and targets are based on expectations and may not reflect the company's current situation.
Get Definitive Healthcare Corp. alerts
New 13F filings, insider trades, and analyst moves on $DH, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.